contraindications / cautions for use of combined oral contraceptive (COC) in terms of risk of cardiovascular disease (CVD)

Last edited 06/2020 and last reviewed 05/2021

  • a combined pill containing a low dose of oestrogen (i.e. 30 mcg) is indicated in women who have migraines without auras - this is because the risk of stroke is greater the higher the dose of oestrogen in the combined pill

  • a DTB review (1) suggested that low-dose pill can also be given to women who have migraines without auras but have one additional risk factor for stroke - however the review emphasises that these patients must be followed up carefully

  • prescribing decisions, with respect to combined hormonal contraception, are made based on the UKMEC criteria below which define migraine with an aura as an absolute contraindication to combined hormonal contraception - see below for further details and guidance with respect to different migraine scenarios

UKMEC Criteria state:

Cardiovascular factors (including migraine) and UKMEC categories (3):

In consideration of UKMEC criteria and combined hormonal contraception (CHC):

 

Check the summary of product characteristics before prescribing any combined oral contraceptive pill.

Reference:

  • (1) Drug and Therapeutics Bulletin (2000), 38 (1), 1-4.
  • (2) BNF 7.3
  • (3) FSRH Clinical Guideline: Combined Hormonal Contraception (January 2019, Amended July 2019)